药物对比
Lasmiditan vs Ubrogepant
Lasmiditan (Reyvow) 与 Ubrogepant (Ubrelvy) 用于偏头痛治疗：Lasmiditan 作用于 5‑HT1F 受体，而 Ubrogepant 阻断 CGRP。两者均为口服药物，且无旧 triptan 类药物的血管收缩风险。
此页面暂无可用的对比维度。
临床背景
Patients experiencing acute migraine who cannot tolerate traditional triptans or have heart-related concerns often compare Lasmiditan and Ubrogepant.
结论
Both Lasmiditan and Ubrogepant offer effective options for acute migraine relief but the optimal choice varies by patient-specific factors.
全部药物对比